Literature DB >> 23884810

Disease duration and the integrity of the nigrostriatal system in Parkinson's disease.

Jeffrey H Kordower1, C Warren Olanow, Hemraj B Dodiya, Yaping Chu, Thomas G Beach, Charles H Adler, Glenda M Halliday, Raymond T Bartus.   

Abstract

The pace of nigrostriatal degeneration, both with regards to striatal denervation and loss of melanin and tyrosine hydroxylase-positive neurons, is poorly understood especially early in the Parkinson's disease process. This study investigated the extent of nigrostriatal degeneration in patients with Parkinson's disease at different disease durations from time of diagnosis. Brains of patients with Parkinson's disease (n=28) with post-diagnostic intervals of 1-27 years and normal elderly control subjects (n=9) were examined. Sections of the post-commissural putamen and substantia nigra pars compacta were processed for tyrosine hydroxylase and dopamine transporter immunohistochemistry. The post-commissural putamen was selected due to tissue availability and the fact that dopamine loss in this region is associated with motor disability in Parkinson's disease. Quantitative assessments of putaminal dopaminergic fibre density and stereological estimates of the number of melanin-containing and tyrosine hydroxylase-immunoreactive neurons in the substantia nigra pars compacta (both in total and in subregions) were performed by blinded investigators in cases where suitable material was available (n=17). Dopaminergic markers in the dorsal putamen showed a modest loss at 1 year after diagnosis in the single case available for study. There was variable (moderate to marked) loss, at 3 years. At 4 years post-diagnosis and thereafter, there was virtually complete loss of staining in the dorsal putamen with only an occasional abnormal dopaminergic fibre detected. In the substantia nigra pars compacta, there was a 50-90% loss of tyrosine hydroxylase-positive neurons from the earliest time points studied with only marginal additional loss thereafter. There was only a ∼10% loss of melanized neurons in the one case evaluated 1 year post-diagnosis, and variable (30 to 60%) loss during the first several years post-diagnosis with more gradual and subtle loss in the second decade. At all time points, there were more melanin-containing than tyrosine hydroxylase-positive cells. Loss of dopaminergic markers in the dorsal putamen occurs rapidly and is virtually complete by 4 years post-diagnosis. Loss of melanized nigral neurons lags behind the loss of dopamine markers. These findings have important implications for understanding the nature of Parkinson's disease neurodegeneration and for studies of putative neuroprotective/restorative therapies.

Entities:  

Keywords:  Parkinsons disease; human brain; morphometry; neuroscience; substantia nigra

Mesh:

Substances:

Year:  2013        PMID: 23884810      PMCID: PMC3722357          DOI: 10.1093/brain/awt192

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  30 in total

1.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

Authors:  M A Piggott; E F Marshall; N Thomas; S Lloyd; J A Court; E Jaros; D Burn; M Johnson; R H Perry; I G McKeith; C Ballard; E K Perry
Journal:  Brain       Date:  1999-08       Impact factor: 13.501

2.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

Authors:  S J Kish; K Shannak; O Hornykiewicz
Journal:  N Engl J Med       Date:  1988-04-07       Impact factor: 91.245

3.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

4.  Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains.

Authors:  Raymond T Bartus; Christopher D Herzog; Yaping Chu; Alistair Wilson; Lamar Brown; Joao Siffert; Eugene M Johnson; C Warren Olanow; Elliott J Mufson; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2010-11-18       Impact factor: 10.338

5.  Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts.

Authors:  S Y Ma; M Röyttä; J O Rinne; Y Collan; U K Rinne
Journal:  J Neurol Sci       Date:  1997-10-03       Impact factor: 3.181

6.  Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra.

Authors:  Yaping Chu; Katie Kompoliti; Elizabeth J Cochran; Elliott J Mufson; Jeffrey H Kordower
Journal:  J Comp Neurol       Date:  2002-08-26       Impact factor: 3.215

7.  Incidental Lewy body disease and preclinical Parkinson disease.

Authors:  Anthony DelleDonne; Kevin J Klos; Hiroshige Fujishiro; Zeshan Ahmed; Joseph E Parisi; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Zbigniew K Wszolek; Ryan J Uitti; J Eric Ahlskog; Dennis W Dickson
Journal:  Arch Neurol       Date:  2008-08

8.  Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.

Authors:  E Hirsch; A M Graybiel; Y A Agid
Journal:  Nature       Date:  1988-07-28       Impact factor: 49.962

9.  Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease.

Authors:  G M Halliday; D A McRitchie; H Cartwright; R Pamphlett; M A Hely; J G Morris
Journal:  J Clin Neurosci       Date:  1996-01       Impact factor: 1.961

10.  Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease.

Authors:  Dennis W Dickson; Hiroshige Fujishiro; Anthony DelleDonne; Joshua Menke; Zeshan Ahmed; Kevin J Klos; Keith A Josephs; Roberta Frigerio; Melinda Burnett; Joseph E Parisi; J Eric Ahlskog
Journal:  Acta Neuropathol       Date:  2008-02-09       Impact factor: 17.088

View more
  353 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.

Authors:  Brian P Mead; Namho Kim; G Wilson Miller; David Hodges; Panagiotis Mastorakos; Alexander L Klibanov; James W Mandell; Jay Hirsh; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  Nano Lett       Date:  2017-05-18       Impact factor: 11.189

Review 3.  Can Biomarkers Help the Early Diagnosis of Parkinson's Disease?

Authors:  Weidong Le; Jie Dong; Song Li; Amos D Korczyn
Journal:  Neurosci Bull       Date:  2017-09-02       Impact factor: 5.203

Review 4.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

5.  Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system.

Authors:  Antonio Martín-Bastida; Nicholas P Lao-Kaim; Andreas Antonios Roussakis; Graham E Searle; Yue Xing; Roger N Gunn; Stefan T Schwarz; Roger A Barker; Dorothee P Auer; Paola Piccini
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

6.  Distinct progression pattern of susceptibility MRI in the substantia nigra of Parkinson's patients.

Authors:  Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang
Journal:  Mov Disord       Date:  2018-05-14       Impact factor: 10.338

7.  Physiological Whole-Brain Distribution of [18F]FDOPA Uptake Index in Relation to Age and Gender: Results from a Voxel-Based Semi-quantitative Analysis.

Authors:  Sinn-Rithy Toch; Sylvain Poussier; Emilien Micard; Marc Bertaux; Axel Van Der Gucht; Elodie Chevalier; Pierre-Yves Marie; Eric Guedj; Antoine Verger
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

Review 8.  α-Synuclein nonhuman primate models of Parkinson's disease.

Authors:  David J Marmion; Jeffrey H Kordower
Journal:  J Neural Transm (Vienna)       Date:  2017-04-22       Impact factor: 3.575

9.  Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease.

Authors:  Ariadna Laguna; Nicoletta Schintu; André Nobre; Alexandra Alvarsson; Nikolaos Volakakis; Jesper Kjaer Jacobsen; Marta Gómez-Galán; Elena Sopova; Eliza Joodmardi; Takashi Yoshitake; Qiaolin Deng; Jan Kehr; Johan Ericson; Per Svenningsson; Oleg Shupliakov; Thomas Perlmann
Journal:  Nat Neurosci       Date:  2015-04-27       Impact factor: 24.884

10.  Mapping the alterations in glutamate with GluCEST MRI in a mouse model of dopamine deficiency.

Authors:  Puneet Bagga; Rachelle Crescenzi; Guruprasad Krishnamoorthy; Gaurav Verma; Ravi Prakash Reddy Nanga; Damodar Reddy; Joel Greenberg; John A Detre; Hari Hariharan; Ravinder Reddy
Journal:  J Neurochem       Date:  2016-10-16       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.